Preclinical studies on the toxicology, pharmacokinetics and safety of K1-70TM a human monoclonal autoantibody to the TSH receptor with TSH antagonist activity
Tóm tắt
The human monoclonal autoantibody K1-70™ binds to the TSH receptor (TSHR) with high affinity and blocks TSHR cyclic AMP stimulation by TSH and thyroid stimulating autoantibodies. The preclinical toxicology assessment following weekly intravenous (IV) or intramuscular (IM) administration of K1-70™ in rats and cynomolgus monkeys for 29 days was carried out. An assessment of delayed onset toxicity and/or reversibility of toxicity was made during a further 4 week treatment free period. The pharmacokinetic parameters of K1-70™ and the effects of different doses of K1-70™ on serum thyroid hormone levels in the study animals were determined in rats and primates after IV and IM administration. Low serum levels of T3 and T4 associated with markedly elevated levels of TSH were observed in the study animals following IV and IM administration of K1-70™. The toxicological findings were attributed to the pharmacology of K1-70™ and were consistent with the hypothyroid state. The no observable adverse effect level (NOAEL) could not be established in the rat study while in the primate study it was 100 mg/kg/dose for both males and females. The toxicology, pharmacodynamic and pharmacokinetic data in this preclinical study were helpful in designing the first in human study with K1-70™ administered to subjects with Graves’ disease.
Tài liệu tham khảo
Rees Smith B, Sanders J, Furmaniak J. TSH receptor antibodies. Thyroid. 2007;17(10):923–38.
Evans M, Sanders J, Tagami T, Sanders P, Young S, Roberts E, et al. Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample. Clin Endocrinol. 2010;73(3):404–12.
Sanders P, Young S, Sanders J, Kabelis K, Baker S, Sullivan A, et al. Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody. J Mol Endocrinol. 2011;46(2):81–99.
Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F. Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian society of endocrinology consensus statement. J Endocrinol Invest. 2015;38:481–7.
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–421.
Kotwal A, Stan M. Current and future treatments for Graves’ disease and Graves’ ophthalmopathy. Horm Metab Res. 2018;50(12):871–86.
Bartalena L. Graves’ orbitopathy: imperfect treatments for a rare disease. Eur Thyroid J. 2013;2(4):259–69.
Perros P, Dayan CM, Dickinson AJ, Ezra D, Estcourt S, Foley P, et al. Management of patients with Graves’ orbitopathy: initial assessment, management outside specialised centres and referral pathways. Clin Med. 2015;15(2):173–8.
Draman MS, Ludgate M. Thyroid eye disease—an update. Expert Rev Ophthalmol. 2016;11(4):273–84.
Beck-Peccoz P. Antithyroid drugs are 65 years old: time for retirement? Endocrinology. 2008;149(12):5943–4.
Emerson CH. When will thyrotropin receptor antagonists and inverse thyrotropin receptor agonists become available for clinical use? Thyroid. 2011;21(8):817–9.
Louvet C, Bellis AD, Pereira B, Bournaud C, Kelly A, Maqdasy S, et al. Time course of Graves’ orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer. Medicine. 2016;95(48):e5474.
Rowe CW, Paul JW, Gedye C, Tolosa JM, Bendinelli C, McGrath S, et al. Targeting the TSH receptor in thyroid cancer. Endocr Relat Cancer. 2017;24(6):R191–202.
Folkestad L, Brandt F, Brix T, Vogsen M, Bastholt L, Grupe P, et al. Total thyroidectomy for thyroid cancer followed by thyroid storm due to thyrotropin receptor antibody stimulation of metastatic thyroid tissue. Eur Thyroid J. 2017;6(5):276–80.
Aoyama M, Takizawa H, Tsuboi M, Nakagawa Y, Tangoku A. A case of metastatic follicular thyroid carcinoma complicated with Graves’ disease after total thyroidectomy. Endocr J. 2017;64(12):1143–7.
Sanders J, Evans M, Premawardhana LD, Depraetere H, Jeffreys J, Richards T, et al. Human monoclonal thyroid stimulating autoantibody. Lancet. 2003;362(9378):126–8.
Furmaniak J, Sanders J, Young S, Kabelis K, Sanders P, Evans M, et al. In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70). Auto Immun Highlights. 2012;3(1):19–25.
Furmaniak J, Sanders J, Rees Smith B. Blocking type TSH receptor antibodies. Autoimmun Highlights. 2013;4:11–26.
Greaves P. Histopathology of preclinical toxicity studies: interpretation and relevance in drug safety evaluation. Chapter 13. 4th ed. Cambridge: Academic Press; 2012. p. 725–97.
Tohei A. Studies on the functional relationship between thyroid, adrenal and gonadal hormones. J Reprod Dev. 2004;50(1):9–20.
Iglesias P, Diez JJ. Thyroid dysfunction and kidney disease. Eur J Endocrinol. 2009;160(4):503–15.
Hard GC, Rodgers IS, Baetcke KP, Richards WL, McGaughy RE, Valcovic LR. Hazard evaluation of chemicals that cause accumulation of α2μ globulin, hyaline droplet nephropathy, and tubule neoplasia in the kedneys of male rats. Environ Health Perspect. 1993;99:313–49.
Vargas F, Moreno JM, Rodriguez-Gomez I, Wangensteen R, Osuna A, Alvarez-Guerra M, et al. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol. 2006;154(2):197–212.
Greaves P. Histopathology of preclinical toxicity studies: interpretation and relevance in drug safety evaluation. Chapter 11. 4th ed. Cambridge: Academic Press; 2012. p. 615–66.
Baht HS, Saggerson ED. A tissue-specific increase in lipogenesis in rat brown adipose tissue in hypothyroidism. Biochem J. 1988;251(2):553–7.
Davies TF, Teng CS, McLachlan SM, Rees Smith B, Hall R. Thyrotropin receptor in adipose tissue, retro-orbital tissue and lymphocytes. Mol Cell Endocrinol. 1978;9(3):303–10.
Davies T, Marians R, Latif R. The TSH receptor reveals itself. J Clin Invest. 2002;110(2):161–4.
de Lloyd A, Bursell J, Gregory JW, Rees DA, Ludgate M. TSH receptor activation and body composition. J Endocrinol. 2010;204(1):13–20.
Williams GR. Extrathyroidal expression of TSH receptor. Ann Endocrinol. 2011;72(2):68–73.
Gershengorn MC, Neumann S. Update in TSH receptor agonists and antagonists. J Clin Endocrinol Metab. 2012;97(12):4287–92.
Squizzato A, Romualdi E, Büller HR, Gerdes VE. Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab. 2007;92(7):2415–20.
Wiersinga WM. Adult hypothyroidism. Thyroid Disease Manager. https://www.thyroidmanager.org/chapter/adult-hypothyroidism/. Accessed 17 July 2019.
Abou-Rabia N, Kendall MD. Involution of the rat thymus in experimentally induced hypothyroidism. Cell Tissue Res. 1994;277(3):447–55.
Vieira P, Rajewsky K. The half-lives of serum immunoglobulins in adult mice. Eur J Immunol. 1988;18(2):313–6.
Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Wroblewski VJ. Monoclonal antibody clearance: impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem. 2007;282(3):1709–17.
Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacomet Syst Parmacol. 2017;6(9):576–88.
FDA. Guidance for industry, estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers, US Department of Health and Human Services, Food and Drug Administration, CDER, July 2005. 2005. https://www.federalregister.gov/d/05-14456. Accessed 17 July 2019.
Nakatake N, Sanders J, Richards T, Burne P, Barrett C, Dal Pra C, et al. Estimation of serum TSH receptor autoantibody concentration and affinity. Thyroid. 2006;16(11):1077–84.
K1-70—a study in subjects with Graves’ disease. https://clinicaltrials.gov/ct2/show/NCT02904330. Accessed 17 July 2019.